How to Rule the Dow in 2012

The following video is part of our "Motley Fool Conversations" series, in which consumer goods editor/analyst Austin Smith and senior technology analyst Eric Bleeker discuss emerging trends in investing.

In today's edition, Eric and Austin discuss some of their expectations for the Dow in 2012. With so many cash-rich companies around, they believe there will be some dividend increases and mergers and acquisitions going forward.

With many emerging markets still at the beginning of their most explosive growth, there is one specially profiled stock we believe will take Latin American retail by storm. There is astounding growth potential for this company The Motley Fool has dubbed our "Top Stock for 2012." The Motley Fool has compiled a special FREE report outlining this company. In it, you'll discover the company hand-picked by our analysts that's positioned to be a titan of retail in the future. You can access the report -- 100% free of charge -- by clicking here. Fool on!

Austin Smith and Eric Bleeker have no positions in the stocks mentioned above. The Motley Fool owns shares of Apple, Dendreon, and Google. Motley Fool newsletter services recommend buying shares of Apple and Google; and creating a bull call spread position in Apple. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (22)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 14, 2012, at 8:31 PM, trysson wrote:

    Every day of the year DNDN does about 8 genome-study-shipments for a fee that (as small as this number is) benefits the future health of "we the people." The potential for growth is great because now the number of clients are few, but the need of the industry is great, and the number of clients will grow quickly. There are too few companies that do this work. The fact of "in-the-right-place-at-the-right-time" is really a key issue with DNDN, and the stock should (must) return to its higher ranges before long. Trysson feels that DNDN is a BUY.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1756484, ~/Articles/ArticleHandler.aspx, 12/19/2014 6:56:50 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement